PRKAR2A

Across TCGA pan-cancer cohorts, PRKAR2A RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of PRKAR2A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PRKAR2A RNA is repressed in tumor relative to normal tissue. In most cancer types PRKAR2A is over-expressed in tumor, although a few such as KIRC and THCA show the opposite, repressed pattern.

KIRC, LIHC, and THCA are the cancer types where PRKAR2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRKAR2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	III,IV	−0.617	<.001	10	view →
LIHC	Male	II,III,IV	+1.145	<.001	9	view →
THCA	Male	III,IV	−0.881	<.001	9	view →
HNSC	Male	All	−0.353	.007	7	view →
STAD	Male	IV	+0.964	.003	5	view →
KICH	All	All	−0.749	<.001	5	view →
LUSC	All	All	−0.260	<.001	4	view →
CHOL	All	All	+0.676	.037	1	view →
KIRP	Male	All	−0.441	.008	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

PRKAR2A–KIRC

Open the KIRC breakdown →